Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer's agitation medications.
A study conducted by researchers from Johns Hopkins University School of Medicine and Tufts University School of Medicine found that a pill form of dronabinol, an FDA-approved synthetic version of THC (the main ingredient in marijuana), reduces agitation in Alzheimer's patients by an average of 30%.
The researchers say that compared to current treatments for agitation, such as antipsychotics, dronabinol produced similar calming effects without adverse results such as delirium or seizures.
Results of the eight-year clinical trial were presented at the International Psychogeriatric Association conference in Buenos Aires, Argentina, on Sept. 26."These new findings represent eight years of work dedicated to people who have Alzheimer's as well as their caregivers," says Paul Rosenberg, M.D., professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine and co-principal investigator for this study. "Agitation is one of the most distressing symptoms of Alzheimer's dementia, and we are pleased to make positive strides forward in the treatment of these patients."
Alzheimer's Agitation and the Need for New Treatments
Alzheimer's disease is the most common neurodegenerative disease in the United States, with an estimated 6.7 million cases in Americans age 65 and older, according to the National Institutes of Health. This number is predicted to grow to 13.8 million by 2060. Agitation is difficult to manage. It is defined as excess motor activity (pacing or repetitive movements), verbal aggression, and/or physical aggression. An estimated 40% of people with Alzheimer's develop agitation.
Although mild agitation can sometimes be moderated by behavioral intervention, in moderate to severe cases, some form of medication is typically required to manage symptoms and provide relief for caregivers."It is the agitation, not the memory loss, that often drives individuals with dementia to the emergency department and long-term-care facilities," says Brent Forester, M.D., psychiatrist-in-chief and chairman of the Department of Psychiatry at Tufts Medical Center and co-principal investigator on the study. "Dronabinol has the potential to both reduce health care costs and make an important, positive impact on caregivers' mental and physical health."
In the new study, researchers recruited 75 patients with severe Alzheimer's agitation across five clinical sites, including 35 admitted to The Johns Hopkins Hospital between March 2017 and May 2024. To qualify, patients had to have a formal clinical diagnosis of Alzheimer's disease and show at least one major symptom of agitation for at least two weeks. Prior to treatment, patients were tested for agitation using the Pittsburgh Agitation Scale (PAS) and the Neuropsychiatric Inventory Agitation/Aggression subscale (NPI-C).
The PAS scores agitation from 0 to 4, with 4 being the most agitated. The NPI-C provides a brief assessment of neuropsychiatric symptoms including delusions, hallucinations, anxiety/depression, and other factors. Baseline scores were acquired from caregivers at the onset of the trial.
Participants were then randomly selected to get either 5 milligrams of dronabinol in pill form or a placebo in pill form twice daily for three weeks, and then retested using the PAS and NPI-C.
Future Research and Cautions
Results from the dronabinol group show an average PAS starting value of 9.68 and an end value of 7.26 after three weeks, a 30% decrease compared to the scores in the placebo group which did not change. Additionally, dronabinol was well tolerated by patients compared to current treatments for agitation."Results like this are encouraging. We are thrilled that FDA-approved dronabinol was robustly effective and appeared safe for treatment of agitation," says Rosenberg. "This adds another tool in our efforts to improve the care of our loved ones with Alzheimer's disease."
The researchers say they plan longer-term studies of dronabinol for Alzheimer's disease, as well as expanded sample sizes. They also hope to continue to explore other ways medical cannabis can benefit both patients and caregivers.
Dronabinol is a synthetic form of THC, the psychoactive main ingredient in cannabis (marijuana). The drug was approved by the U.S. Food and Drug Administration in 1985 to treat loss of appetite in patients with HIV/AIDS, and is currently prescribed to treat nausea and vomiting in those undergoing cancer chemotherapy.
The investigators caution that their current study results are not intended to encourage or inform the use of other forms of medical marijuana available in 38 states and the District of Columbia.
Meeting: International Psychogeriatric Association conference
Co-investigators include Halima Amjad, Haroon Burhanullah and Milap Nowrangi at the Johns Hopkins University School of Medicine, Marc Agronin at Miami Jewish Health, and James Wilkins and David Harper at McLean Hospital.
The study was funded by a grant from the National Institute of Aging at the National Institutes of Health.
News
New Toothpaste Stops Gum Disease Without Harming Healthy Bacteria
Researchers have developed a targeted approach to combat periodontitis without disrupting the natural balance of the oral microbiome. The innovation could reshape how gum disease is treated while preserving beneficial bacteria. The human mouth [...]
Plastic Without End: Are We Polluting the Planet for Eternity?
The Kunming Montreal Global Biodiversity Framework calls for the elimination of plastic pollution by 2030. If that goal has been clearly set, why have meaningful measures that create real change still not been implemented? [...]
Scientists Rewire Natural Killer Cells To Attack Cancer Faster and Harder
Researchers tested new CAR designs in NK-92 cells and found the modified cells killed tumor cells more effectively, showing stronger anti-cancer activity. Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based [...]
New “Cellular” Target Could Transform How We Treat Alzheimer’s Disease
A new study from researchers highlights an unexpected player in Alzheimer’s disease: aging astrocytes. Senescent astrocytes have been identified as a major contributor to Alzheimer’s progression. The cells lose protective functions and fuel inflammation, particularly in [...]
Treating a Common Dental Infection… Effects That Extend Far Beyond the Mouth
Successful root canal treatment may help lower inflammation associated with heart disease and improve blood sugar and cholesterol levels. Treating an infected tooth with a successful root canal procedure may do more than relieve [...]
Microplastics found in prostate tumors in small study
In a new study, researchers found microplastics deep inside prostate cancer tumors, raising more questions about the role the ubiquitous pollutants play in public health. The findings — which come from a small study of 10 [...]
All blue-eyed people have this one thing in common
All Blue-Eyed People Have This One Thing In Common Blue Eyes Aren’t Random—Research Traces Them Back to One Prehistoric Human It sounds like a myth at first — something you’d hear in a folklore [...]
Scientists reveal how exercise protects the brain from Alzheimer’s
Researchers at UC San Francisco have identified a biological process that may explain why exercise sharpens thinking and memory. Their findings suggest that physical activity strengthens the brain's built in defense system, helping protect [...]
NanoMedical Brain/Cloud Interface – Explorations and Implications. A new book from Frank Boehm
New book from Frank Boehm, NanoappsMedical Inc Founder: This book explores the future hypothetical possibility that the cerebral cortex of the human brain might be seamlessly, safely, and securely connected with the Cloud via [...]
Deadly Pancreatic Cancer Found To “Wire Itself” Into the Body’s Nerves
A newly discovered link between pancreatic cancer and neural signaling reveals a promising drug target that slows tumor growth by blocking glutamate uptake. Pancreatic cancer is among the most deadly cancers, and scientists are [...]
This Simple Brain Exercise May Protect Against Dementia for 20 Years
A long-running study following thousands of older adults suggests that a relatively brief period of targeted brain training may have effects that last decades. Starting in the late 1990s, close to 3,000 older adults [...]
Scientists Crack a 50-Year Tissue Mystery With Major Cancer Implications
Researchers have resolved a 50-year-old scientific mystery by identifying the molecular mechanism that allows tissues to regenerate after severe damage. The discovery could help guide future treatments aimed at reducing the risk of cancer [...]
This New Blood Test Can Detect Cancer Before Tumors Appear
A new CRISPR-powered light sensor can detect the faintest whispers of cancer in a single drop of blood. Scientists have created an advanced light-based sensor capable of identifying extremely small amounts of cancer biomarkers [...]
Blindness Breakthrough? This Snail Regrows Eyes in 30 Days
A snail that regrows its eyes may hold the genetic clues to restoring human sight. Human eyes are intricate organs that cannot regrow once damaged. Surprisingly, they share key structural features with the eyes [...]
This Is Why the Same Virus Hits People So Differently
Scientists have mapped how genetics and life experiences leave lasting epigenetic marks on immune cells. The discovery helps explain why people respond so differently to the same infections and could lead to more personalized [...]
Rejuvenating neurons restores learning and memory in mice
EPFL scientists report that briefly switching on three “reprogramming” genes in a small set of memory-trace neurons restored memory in aged mice and in mouse models of Alzheimer’s disease to level of healthy young [...]
